Jean-Dominique Béhéty has devoted his entire career to the medical devices industry. He started as a qualification technician at Ela Medical in the early 1990s. After that he joined SAIME, which became ResMed Paris, a leading player in the field of in-home and hospital respiratory support, where he successively held several positions and ultimately managed the Group's last industrial site in Europe. His tasks included spearheading strategic changes, particularly overhauling processes and developing a service-based business. Starting in 2018 he broadened his field of expertise by engaging in various entrepreneurial projects before joining Affluent Medical.
Upcoming events
27 and 28 September 2021: Investor Access Forum, Paris, France
4 and 5 October 2021: HealthTech Innovation Days, Paris, France
21 and 22 October 2021: Midcap Event Forum, Paris, France
23 November 2021 : Investir Day, Paris
About Affluent Medical
Affluent Medical is a French player in MedTech, founded by Truffle Capital, with the aim of becoming a global leader in the treatment of heart and vascular diseases, which are the leading cause of death worldwide, and of urinary incontinence, which today affects one in four adults. Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas. The four major technologies developed by the Company are currently in the preclinical and clinical study phase. The first medical device should be marketed and sold by 2023 with Kalios in Europe.
For more information, please visit: www.affluentmedical.com
Contacts:
AFFLUENT MEDICAL ACTIFIN, financial communication Jérôme Geoffroy Ghislaine Gasparetto Chief Financial Officer +33 (0)6 21 10 49 24 investor@affluentmedical.com affluentmedical@actifin.fr ACTIFIN, financial press relations DGM, corporate press relations Jennifer Jullia Thomas Roborel de Climens +33 (0)6 47 97 54 87 +33 (0)6 14 50 15 84 jjullia@actifin.fr thomasdeclimens@dgm-conseil.fr
-----------------------------------------------------------------------------------------------------------------------
[1] NYHA: The NYHA classification is a scale of the clinical severity of heart failure that has diagnostic, prognostic and therapeutic value.
-----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file File: Affluent Medical - H1 2021 EN
=----------------------------------------------------------------------
Language: English
Company: Affluent Medical
320 avenue Archimède, Les pléiades III Bâtiment B
13100 Aix en Provence France
France
Phone: +33 4 42 95 12 20
E-mail: jerome.geoffroy@affluentmedical.com
Internet: https://www.affluentmedical.com/
ISIN: FR0013333077
Euronext Ticker: AFME
AMF Category: Inside information / News release on accounts, results
EQS News ID: 1235364
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
1235364 22-Sep-2021 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1235364&application_name=news
(END) Dow Jones Newswires
September 22, 2021 11:45 ET (15:45 GMT)